Traumatic fractures across the lifespan often require hospitalization, surgery, frequent physician visits, and lost time from work. More than 5 million Americans suffer from fractures annually.  Each year an estimated 1.5 million individuals in the United States suffer a fracture just due to bone disease.

The global bone regeneration market is set to witness a valuation of US$ 5,380.75 million in 2023, and further expand at a CAGR of 3.8% to reach US$ 7,827.8 million by 2033. In terms of product type, bone graft substitutes led the market with a share of 81.2% in 2022.

The morbidity associated with fracture healing is high and yet the effective treatment to accelerate fracture healing is still lacking. We estimate that Rab-001 could become a “stable” ingredient for bone fracture healing in the US in excess of $300 million+ per year. Given the patent and intellectual property portfolio for the drug, these sales could last 15+ or more years.